SOURCE: ProPhotonix Limited

September 06, 2016 02:17 ET

ProPhotonix Introduces the Cobra Cure FX3

SALEM, NEW HAMPSHIRE--(Marketwired - Sep 6, 2016) - ProPhotonix Limited (OTC PINK: STKR) (LSE: PPIX) -

OTC: STKR; AIM: PPIX

ProPhotonix extends COBRA CURE FX Series with 16 W/cm2 Higher Power Fan-cooled UV Curing System
Compact, UV LED Solution featuring an innovative configurable design, stackable and other unique features

(Salem, New Hampshire, September 6, 2016) ProPhotonix Limited (OTC: STKR and London Stock Exchange - AIM: PPIX), ProPhotonix Limited, a high technology designer and manufacturer of LED illumination systems and laser diode modules, announces the COBRA Cure FX3, an extension to its UV LED Curing systems. The COBRA Cure FX3 is the highest intensity air cooled product in ProPhotonix' UV family. 

The COBRA Cure FX3 follows from the previously announced COBRA Cure FX1, which produces a uniform line with a peak irradiance of 6 W/cm2 and peak energy density (dose) of 5 J/cm2 and the COBRA Cure FX2, which produces a uniform line with a peak irradiance of 8.4 W/cm2 and energy densities up to 17.5 J/cm2. The COBRA Cure FX3 delivers best-in-class intensities up to 16 W/cm2 and energy densities up to 42 J/cm2.

The COBRA Cure FX3 is scalable without any drop in intensity from module to module ensuring consistent edge-to-edge illumination. The design is unique incorporating surge protection, LED segment control, and power control between 5% and 100%. The control of each LED segment is designed to monitor and drive each LED segment providing consistent intensity control across the entire illumination area. Wavelength options include 365nm, 385nm, 395nm, and 405nm configurations as well as integrated multi-wavelength options.

Tim Losik, CEO and President of ProPhotonix, said "ProPhotonix (IRL) Limited has been a pioneer in LED technology since 1994 and a provider of UV LED solutions since 2006. As an early adopter of LED chip-on-board technology, ProPhotonix provides high intensity illumination across all LED wavelengths - including UV. The FX3 adds to our broad range of UV LED products providing more illumination options for our customers. Estimates are that market demand for UV LED systems will grow at nearly 40% per annum through 2019 to $500 million. We are uniquely positioned to significantly participate in this high growth market and deliver ongoing enhancements to our customers."

For more information about COBRA Cure FX3, visit www.prophotonix.com/products/UV-Solutions.

Contact:

ProPhotonix Limited
Simon Stanley, Managing Director, Ireland Sales

+353-21500-01300 sales@prophotonix.com

About ProPhotonix
ProPhotonix Limited, headquartered in Salem, New Hampshire, is a high technology designer and manufacturer of diode-based laser modules and LED systems for industry leading OEMs and medical equipment companies. In addition, the Company distributes premium diodes for Ushio (formerly Oclaro), Osram, QSI, Panasonic, and Sony. The Company serves a wide range of markets including the machine vision, industrial inspection, security, and medical markets. ProPhotonix has offices and subsidiaries in the U.S., Ireland, U.K., and Europe. For more information about ProPhotonix and its innovative products, visit the Company's web site at www.prophotonix.com

Cautionary Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact, including without limitation, those with respect to ProPhotonix's goals, plans and strategies set forth herein are forward-looking statements. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: uncertainty that cash balances may not be sufficient to allow ProPhotonix to meet all of its business goals; uncertainty that ProPhotonix's new products will gain market acceptance; the risk that delays and unanticipated expenses in developing new products could delay the commercial release of those products and affect revenue estimates; the risk that one of our competitors could develop and bring to market a technology that is superior to those products that we are currently developing; and ProPhotonix's ability to capitalize on its significant research and development efforts by successfully marketing those products that the Company develops. Forward-looking statements represent management's current expectations and are inherently uncertain. All Company, brand, and product names are trademarks or registered trademarks of their respective holders. ProPhotonix undertakes no duty to update any of these forward-looking statements.

This information is provided by RNS
The company news service from the London Stock Exchange

END

Contact Information